← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
  1. Home
  2. JNJ
  3. P/E History
OverviewAnalysisPriceRevenueEarningsP/ERatiosDividendTargetsShould I Buy?

JNJ logoJohnson & Johnson (JNJ) P/E Ratio History

Historical price-to-earnings valuation from 1990 to 2025

Current P/E
39.0
Overvalued
5Y Avg P/E
22.0
+77% vs avg
PE Percentile
100%
High
PEG Ratio
N/A
N/A
TTM EPS$10.34
Price$225.59
5Y PE Range9.6 - 33.5
Earnings Yield2.57%

Loading P/E history...

JNJ Valuation Context

How does the current P/E compare to historical and market benchmarks?

vs. 5Y Average
39.0vs22.0
+77%
Premium vs History
vs. Healthcare
39.0vs22.2
+76%
Above Sector
vs. S&P 500
39.0vs25.1
+55%
Above Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on -58% EPS growth (1Y)
Export Data

P/E Ratio Analysis

As of May 6, 2026, Johnson & Johnson (JNJ) trades at a price-to-earnings ratio of 39.0x, with a stock price of $225.59 and trailing twelve-month earnings per share of $10.34.

The current P/E is 77% above its 5-year average of 22.0x. Over the past five years, JNJ's P/E has ranged from a low of 9.6x to a high of 33.5x, placing the current valuation at the 100th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.2x, JNJ trades at a 76% premium to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 171.0x.

Relative to the broader market, JNJ commands a significant premium over the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our JNJ DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

JNJ P/E vs Peers

P/E ratio compared to closely matched public peers

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
ABT logoABTAbbott Laboratories
$152B11.4Lowest0.38Best+134%
PFE logoPFEPfizer Inc.
$150B19.4--4%
MRK logoMRKMerck & Co., Inc.
$279B15.50.73+8%
LLY logoLLYEli Lilly and Company
$934B43.11.49+96%
BMY logoBMYBristol-Myers Squibb Company
$116B16.5-+178%Best
ABBV logoABBVAbbVie Inc.
$365B87.0--1%
NVS logoNVSNovartis AG
$278B20.21.32+22%
SYK logoSYKStryker Corporation
$113B35.12.36+8%
MDT logoMDTMedtronic plc
$100B21.5-+31%
BSX logoBSXBoston Scientific Corporation
$83B28.9-+55%

Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.

JNJ Historical P/E Data (1990–2025)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterDatePriceTTM EPSP/E Ratiovs Avg
FY2025 Q3Sun Sep 28 2025 00:00:00 GM$179.71$10.3617.3x-44%
FY2025 Q2Sun Jun 29 2025 00:00:00 GM$152.41$9.3516.3x-47%
FY2025 Q1Sun Mar 30 2025 00:00:00 GM$163.71$8.9918.2x-41%
FY2024 Q4Sun Dec 29 2024 00:00:00 GM$145.05$5.7925.1x-19%
FY2024 Q3Sun Sep 29 2024 00:00:00 GM$161.40$6.0526.7x-13%
FY2024 Q2Sun Jun 30 2024 00:00:00 GM$146.16$15.159.6x-69%
FY2024 Q1Sun Mar 31 2024 00:00:00 GM$158.19$15.1810.4x-66%
FY2023 Q4Sun Dec 31 2023 00:00:00 GM$156.74$13.8111.3x-63%
FY2023 Q3Sun Oct 01 2023 00:00:00 GM$155.75$13.4711.6x-62%
FY2023 Q2Sun Jul 02 2023 00:00:00 GM$165.52$4.9433.5x+9%
FY2023 Q1Sun Apr 02 2023 00:00:00 GM$155.00$4.7832.4x+5%
FY2022 Q4Sat Dec 31 2022 00:00:00 GM$176.65$6.7426.2x-15%

Average P/E for displayed period: 30.8x

Full JNJ Stock Analysis

Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.

View Analysis

Should I Buy JNJ Right Now?

Bull case, key risks, Wall St analyst verdict, and what council investors are saying — updated daily.

See Verdict

See JNJ's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is JNJ Undervalued?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

Compare JNJ vs DBVT

Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..

Start Comparison

JNJ — Frequently Asked Questions

Quick answers to the most common questions about buying JNJ stock.

Is JNJ stock overvalued or undervalued?

JNJ trades at 39.0x P/E, above its 5-year average of 22.0x. The 100th percentile ranking indicates a premium to historical valuation.

How does JNJ's valuation compare to peers?

Johnson & Johnson P/E of 39.0x compares to sector median of 22.2x. The premium reflects expected growth above peers.

What is JNJ's PEG ratio?

JNJ PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 1990-2025.

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.

JNJ P/E Ratio History (1990–2025)

P/E ratio calculated as closing price divided by trailing 12-month diluted EPS at each quarter end.